NCT04925557: A trial that was reported late by State University of New York at Buffalo
This trial has reported, although it was 215 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04925557 |
|---|---|
| Title | Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 13, 2021 |
| Completion date | June 1, 2023 |
| Required reporting date | May 31, 2024, midnight |
| Actual reporting date | Jan. 2, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 215 |